As a heart transplant recipient less than three years out from quadruple organ failure, and a father of two young children, I'm not just hoping that modernization will save and extend more lives. I'm counting on it.
OmniLIfe Health, based in Lexington, Kentucky, won the MedCity News INVEST Pitch Perfect contest on May 23, beating five other payer/provider startups. The company works to streamline workflows for organ transplants.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Paragonix Technologies recently closed a $24 million Series B funding round. The Cambridge, Massachusetts-based company provides transplant centers and organ procurement organizations with medical devices designed for the preservation and transportation of donor organs.
Quell Therapeutics' $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate as way to prevent organ rejection in liver transplant patients. The progress is part of a growing field of Treg cell therapy developers that is becoming increasingly competitive.
Takeda Pharmaceutical won FDA approval for Livtencity, an antiviral developed to treat cytomegalovirus infection in transplant patients. The agency also approved an Aadi Biosciences drug, making it the first therapy authorized for treating a rare type of soft-tissue cancer.
A Novartis drug intended to prevent organ rejection has failed to beat out the standard of care therapy in a Phase 2 study in kidney transplant patients. Other clinical trial failures announced ahead of the Labor Day weekend include a Forte Biosciences atopic dermatitis drug, as well a cancer therapy from Takeda Pharmaceutical.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Three biotechs IPOs priced this week while one gene therapy developer postponed its plans. The biggest IPO belongs to Talaris Therapeutics, a company developing a cell therapy for organ transplant patients that could mean the end of lifelong immunosuppressive drugs that prevent rejection.
The standard for organ transplant is a plastic picnic cooler filled with ice. Boston-based TransMedics is one-upping this idea with a warm blood perfusion device - essentially keeping organs alive as they await transplant surgery.
A 6.6 pound baby girl sadly suffered irreparable brain damage in the womb, but for the first time in Britain, surgeons were able to transplant her kidneys, which were transplanted into a patient with renal failure, and liver cells, which were donated to a second recipient who had liver damage. Doctors tried to revive the […]